Loading...

Syndax Pharmaceuticals

Nasdaq:SNDX
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SNDX
Nasdaq
$243M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The last earnings update was 69 days ago. More info.


Add to Portfolio Compare Print
  • Syndax Pharmaceuticals has significant price volatility in the past 3 months.
SNDX Share Price and Events
7 Day Returns
-4.9%
NasdaqGS:SNDX
-2.3%
US Biotechs
0.8%
US Market
1 Year Returns
22%
NasdaqGS:SNDX
-11.9%
US Biotechs
4.8%
US Market
SNDX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Syndax Pharmaceuticals (SNDX) -4.9% 16.5% 43.2% 22% -24.2% -
US Biotechs -2.3% 2.3% -4.3% -11.9% 8.5% 10.3%
US Market 0.8% 4.3% 2.8% 4.8% 37.9% 43.5%
1 Year Return vs Industry and Market
  • SNDX outperformed the Biotechs industry which returned -11.9% over the past year.
  • SNDX outperformed the Market in United States of America which returned 4.8% over the past year.
Price Volatility
SNDX
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Syndax Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Syndax Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Syndax Pharmaceuticals.

NasdaqGS:SNDX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:SNDX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.33
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.327 (1 + (1- 21%) (0.56%))
1.223
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.22
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.223 * 5.96%)
10.02%

Discounted Cash Flow Calculation for NasdaqGS:SNDX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Syndax Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:SNDX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.02%)
2020 -69.45 Analyst x2 -63.13
2021 -76.00 Analyst x1 -62.79
2022 -11.00 Analyst x1 -8.26
2023 90.00 Analyst x1 61.43
2024 146.33 Est @ 62.59% 90.79
2025 211.65 Est @ 44.63% 119.35
2026 279.50 Est @ 32.06% 143.27
2027 344.53 Est @ 23.26% 160.52
2028 403.45 Est @ 17.1% 170.86
2029 455.05 Est @ 12.79% 175.16
Present value of next 10 years cash flows $787.20
NasdaqGS:SNDX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $455.05 × (1 + 2.73%) ÷ (10.02% – 2.73%)
$6,414.72
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $6,414.72 ÷ (1 + 10.02%)10
$2,469.21
NasdaqGS:SNDX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $787.20 + $2,469.21
$3,256.41
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $3,256.41 / 27.10
$120.18
NasdaqGS:SNDX Discount to Share Price
Calculation Result
Value per share (USD) From above. $120.18
Current discount Discount to share price of $8.98
= -1 x ($8.98 - $120.18) / $120.18
92.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Syndax Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is $8.98 vs Future cash flow value of $120.18
Current Discount Checks
For Syndax Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Syndax Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Syndax Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Syndax Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Syndax Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:SNDX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-2.65
NasdaqGS:SNDX Share Price ** NasdaqGS (2019-07-15) in USD $8.98
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,084 Publicly-Listed Companies 18.01x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Syndax Pharmaceuticals.

NasdaqGS:SNDX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:SNDX Share Price ÷ EPS (both in USD)

= 8.98 ÷ -2.65

-3.39x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Syndax Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • Syndax Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Syndax Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGS:SNDX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.39x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
25.8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 0.81x
United States of America Market PEG Ratio Median Figure of 2,124 Publicly-Listed Companies 1.59x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Syndax Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Syndax Pharmaceuticals's assets?
Raw Data
NasdaqGS:SNDX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.53
NasdaqGS:SNDX Share Price * NasdaqGS (2019-07-15) in USD $8.98
United States of America Biotechs Industry PB Ratio Median Figure of 436 Publicly-Listed Biotechs Companies 2.98x
United States of America Market PB Ratio Median Figure of 5,240 Publicly-Listed Companies 1.81x
NasdaqGS:SNDX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:SNDX Share Price ÷ Book Value per Share (both in USD)

= 8.98 ÷ 2.53

3.55x

* Primary Listing of Syndax Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Syndax Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Syndax Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Syndax Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Syndax Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
25.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Syndax Pharmaceuticals expected to grow at an attractive rate?
  • Syndax Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Syndax Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Syndax Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:SNDX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:SNDX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 25.8%
NasdaqGS:SNDX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 81.1%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23.2%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:SNDX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:SNDX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 256 337 21 4
2022-12-31 83 206 -58 3
2021-12-31 33 -22 -69 5
2020-12-31 12 -77 -78 7
2019-12-31 1 -54 -60 7
NasdaqGS:SNDX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 2 -65 -69
2018-12-31 2 -69 -74
2018-09-30 2 -66 -74
2018-06-30 2 -58 -72
2018-03-31 2 -55 -67
2017-12-31 2 -47 -61
2017-09-30 1 -45 -53
2017-06-30 1 -46 -52
2017-03-31 1 -41 -47
2016-12-31 1 -35 -47
2016-09-30 1 -29 -45
2016-06-30 1 -23 -87

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Syndax Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Syndax Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:SNDX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Syndax Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:SNDX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.61 2.41 -0.80 3.00
2022-12-31 -0.84 -0.19 -1.44 3.00
2021-12-31 -1.93 -1.65 -2.09 3.00
2020-12-31 -2.23 -1.57 -3.19 6.00
2019-12-31 -2.00 -1.68 -2.19 6.00
NasdaqGS:SNDX Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -2.65
2018-12-31 -2.92
2018-09-30 -3.01
2018-06-30 -3.02
2018-03-31 -2.98
2017-12-31 -2.90
2017-09-30 -2.69
2017-06-30 -2.84
2017-03-31 -2.61
2016-12-31 -3.22
2016-09-30 -4.47
2016-06-30 -15.44

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Syndax Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Syndax Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Syndax Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Syndax Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Syndax Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Syndax Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Syndax Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Syndax Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Syndax Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Syndax Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:SNDX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 1.52 -68.87 16.41 56.05
2018-12-31 1.52 -73.96 17.29 60.11
2018-09-30 2.33 -74.23 17.48 60.88
2018-06-30 2.26 -71.98 16.92 58.98
2018-03-31 2.18 -67.23 16.72 53.99
2017-12-31 2.11 -60.80 15.86 48.20
2017-09-30 1.22 -52.51 14.75 39.98
2017-06-30 1.22 -52.39 14.46 40.06
2017-03-31 1.22 -47.11 12.98 36.33
2016-12-31 1.22 -47.07 13.32 31.67
2016-09-30 1.22 -45.03 11.45 25.78
2016-06-30 1.22 -86.72 11.37 16.47
2016-03-31 0.93 -104.70 11.85 12.61
2015-12-31 0.63 -103.85 11.59 9.55
2015-09-30 0.32 -100.26 11.03 8.42
2015-06-30 0.02 -53.02 13.86 7.76
2015-03-31 -32.80 12.02 9.76
2014-12-31 -26.36 11.16 10.18
2014-09-30 -31.14 11.14 9.78
2014-06-30 -72.27 6.56 8.32
2014-03-31 -66.64 6.47 4.77
2013-12-31 -60.45 5.36 3.21
2013-09-30 -53.18 3.93 2.78
2012-12-31 -9.97 3.49 5.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Syndax Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Syndax Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Syndax Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Syndax Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Syndax Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Syndax Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Syndax Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Syndax Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Syndax Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Syndax Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Syndax Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Syndax Pharmaceuticals Company Filings, last reported 3 months ago.

NasdaqGS:SNDX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 68.63 0.00 95.37
2018-12-31 53.05 0.00 81.57
2018-09-30 64.27 0.00 91.52
2018-06-30 70.35 0.00 99.79
2018-03-31 86.95 0.00 113.99
2017-12-31 104.32 0.00 131.26
2017-09-30 96.71 0.00 121.49
2017-06-30 109.34 0.00 131.96
2017-03-31 72.62 0.00 95.20
2016-12-31 84.14 0.00 106.96
2016-09-30 93.83 0.00 116.00
2016-06-30 106.24 0.00 125.89
2016-03-31 113.85 0.00 134.32
2015-12-31 66.70 0.00 87.29
2015-09-30 70.76 8.18 100.46
2015-06-30
2015-03-31 -5.72 13.88 12.21
2014-12-31 -5.72 13.88 12.21
2014-09-30 -2.58 9.82 11.69
2014-06-30 4.31 0.00 5.01
2014-03-31 8.43 0.00 9.50
2013-12-31 11.85 0.00 14.26
2013-09-30 -4.48 1.49 5.07
2012-12-31 -27.47 21.34 0.63
  • Syndax Pharmaceuticals has no debt.
  • Syndax Pharmaceuticals had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Syndax Pharmaceuticals has sufficient cash runway for 1.5 years based on current free cash flow.
  • Syndax Pharmaceuticals has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 35.4% each year.
X
Financial health checks
We assess Syndax Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Syndax Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Syndax Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Syndax Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of Syndax Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Syndax Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Syndax Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:SNDX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2018 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:SNDX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Syndax Pharmaceuticals has not reported any payouts.
  • Unable to verify if Syndax Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Syndax Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Syndax Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Syndax Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Syndax Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Syndax Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Syndax Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Syndax Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Briggs Morrison
COMPENSATION $2,080,513
AGE 59
TENURE AS CEO 4.1 years
CEO Bio

Dr. Briggs W. Morrison, M.D. serves as the Executive Partner MPM Capital. He joined MPM in 2015. He is the Chairman of Scientific Advisory Board at Cerenis Therapeutics Holding SA since May 2018. Dr. Morrison has been the Chief Executive Officer of Syndax Pharmaceuticals, Inc. since June 22, 2015. Dr. Morrison has been Managing Director at MPM Capital since June 22, 2015. Dr. Morrison joined MPM Capital in 2015. He served as an Executive Vice President for Global Medicines Development and Chief Medical Officer at AstraZeneca PLC from January 2012 to June 2015. In his role as Head of Global Medicines Development, Dr. Morrison oversaw all clinical development functions and late stage clinical development projects at AstraZeneca. During his tenure, AstraZeneca rebuilt its Phase 3 pipeline with a focus on Oncology, Respiratory and Cardiovascular/Metabolic molecules. He served as a Senior Vice President/Head of Clinical Development of Pfizer Inc. since October 4, 2007 until January 2012. He held a number of positions at Pfizer Inc. from 2007 to 2012 that culminated in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizerâ s human health business. Dr. Morrison serves as a Director of Arvinas, Inc since June 2018. Dr. Morrison was responsible for the clinical development of all compounds in Pfizer's portfolio, he played a key role in implementing strategies to advance key compounds to approval. He oversaw Phase I – III development for all therapeutic areas as well as clinical operations. He later oversaw Development, Medical Affairs, Safety and Regulatory Affairs for all Pfizer human health businesses and served as Head of the Medicines Development Group for the Primary Care Business Unit, overseeing Development, Medical Affairs, Market Access and early commercial development. Previously, Dr. Morrison served as Senior Vice President of Research Planning and Integration of Merck & Co., Inc. and its head of Global Clinical Development Operations. He served in senior research and clinical data management positions as Executive Director and Vice President for all Clinical Data Management Operations, where he was responsible for all clinical data management across the entire research portfolio. He worked at Merck Research Laboratories from 1995 to 2007, ascending to the role of Vice President, Clinical Sciences, Oncology, responsible for clinical development of all novel anti-cancer drugs. He also worked as the Head of the Oncology Development group at Merck & Co., Inc., overseeing the development and approval of vorinostat (Zolinza) for the treatment of cutaneous T-cell lymphoma. From 2004 to 2006, he was on a special assignment to review and enhance the effectiveness of Merck's research operations and led the restructuring of the research division and its processes. He served as Chairman of the Board of Transcelerate BioPharma from 2014 to 2015. He serves as Board of Director of ACRES (Alliance for Clinical Research Excellence and Safety), ImunoMet Therapeutics, Inc. and Oncorus, Inc. He has been a Director of Codiak Biosciences, Inc. since February 2018. He has been a Director of RIFT Biotherapeutics Inc. since March 2017 and NextCure, Inc. since April 2019. He has been a Member of Advisory Board of Tyme Technologies, Inc. since September 14, 2017. Dr. Morrison has been a Director of Syndax Pharmaceuticals, Inc. since July 2015 and ImmunoMet Therapeutics, Inc. since November 28, 2017. He is an instructor in medicine at the Harvard Medical School. He completed his internship and residency in Internal Medicine at the Massachusetts General Hospital, a fellowship in Medical Oncology at the Dana-Farber Cancer Institute and a post-doctoral research fellowship in Genetics at Harvard Medical School. Dr. Morrison received a B.S. in Biology from Georgetown University and holds an M.D. from the University of Connecticut School of Medicine.

CEO Compensation
  • Briggs's compensation has increased whilst company is loss making.
  • Briggs's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Syndax Pharmaceuticals management team in years:

4.1
Average Tenure
60.5
Average Age
  • The tenure for the Syndax Pharmaceuticals management team is about average.
Management Team

Briggs Morrison

TITLE
CEO & Director
COMPENSATION
$2M
AGE
59
TENURE
4.1 yrs

Michael Metzger

TITLE
President
COMPENSATION
$2M
AGE
48
TENURE
4.2 yrs

Michael Meyers

TITLE
Chief Medical Officer & Senior VP
COMPENSATION
$1M
AGE
68
TENURE
3.9 yrs

Peter Ordentlich

TITLE
Co-Founder & Chief Scientific Officer
AGE
50
TENURE
13.8 yrs

Rich Heyman

TITLE
Co-Founder
AGE
62

Ronald Evans

TITLE
Co-Founder

Michael Downes

TITLE
Co-Founder

Rick Shea

TITLE
CFO & Treasurer
COMPENSATION
$13K
AGE
67
TENURE
2.4 yrs

Luke Albrecht

TITLE
General Counsel & Corporate Secretary

Ed Sausville

TITLE
Board of Directors Tenure

Average tenure and age of the Syndax Pharmaceuticals board of directors in years:

3.3
Average Tenure
57.5
Average Age
  • The tenure for the Syndax Pharmaceuticals board of directors is about average.
Board of Directors

Dennis Podlesak

TITLE
Chairman
COMPENSATION
$245K
AGE
61
TENURE
10.6 yrs

Briggs Morrison

TITLE
CEO & Director
COMPENSATION
$2M
AGE
59
TENURE
4 yrs

Michael Metzger

TITLE
President
COMPENSATION
$2M
AGE
48

Ronald Evans

TITLE
Co-Founder
TENURE
3 yrs

Pierre Legault

TITLE
Director
COMPENSATION
$223K
AGE
58
TENURE
2.5 yrs

Keith Katkin

TITLE
Director
COMPENSATION
$210K
AGE
48
TENURE
2.3 yrs

George Sledge

TITLE
Member of Scientific Advisory Board
COMPENSATION
$23K
AGE
67
TENURE
2.3 yrs

Jay Lichter

TITLE
Observer
AGE
57

Fabrice Egros

TITLE
Director
COMPENSATION
$200K
AGE
56
TENURE
5.8 yrs

Julie Brahmer

TITLE
Member of Scientific Advisory Board
TENURE
3.6 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Syndax Pharmaceuticals individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
13. May 19 Buy Briggs Morrison Individual 09. May 19 13. May 19 20,400 $7.56 $152,243
25. Mar 19 Buy Michael Meyers Individual 21. Mar 19 21. Mar 19 1,112 $4.93 $5,475
07. Nov 18 Buy Michael Meyers Individual 30. Oct 18 30. Oct 18 200 $4.79 $958
X
Management checks
We assess Syndax Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Syndax Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Should Investors React To Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) CEO Pay?

See our latest analysis for Syndax Pharmaceuticals How Does Briggs Morrison's Compensation Compare With Similar Sized Companies? … While we always look at total compensation first, we note that the salary component is less, at US$566k. … We compared total CEO remuneration at Syndax Pharmaceuticals, Inc.

Simply Wall St -

Is Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) CEO Pay Justified?

See our latest analysis for Syndax Pharmaceuticals How Does Briggs Morrison's Compensation Compare With Similar Sized Companies? … We examined companies with market caps from US$100m to US$400m, and discovered that the median CEO total compensation of that group was US$1.2m. … Thus we can conclude that Briggs Morrison receives more in total compensation than the median of a group of companies in the same market, and of similar size to Syndax Pharmaceuticals, Inc..

Simply Wall St -

Some Syndax Pharmaceuticals (NASDAQ:SNDX) Shareholders Are Down 46%

In fact, the share price is down 46% in the last three years, falling well short of the market return. … That probably explains why the share price is down 19% per year, over 3 years. … Shareholders have lost 19% per year over the last three years, so the share price drop has become steeper, over the last year; a potential symptom of as yet unsolved challenges.

Simply Wall St -

Could The Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Ownership Structure Tell Us Something Useful?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … With a market capitalization of US$174m, Syndax Pharmaceuticals is a small cap stock, so it might not be well known by many institutional investors. … institutions own shares in the company.

Simply Wall St -

What Should Investors Know About Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Earnings Trend?

The latest earnings announcement Syndax Pharmaceuticals, Inc. … (NASDAQ:SNDX) released in December 2018 … company earnings became less negative compared to the previous year's level

Simply Wall St -

What Did Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) CEO Take Home Last Year?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Briggs Morrison's Compensation Compare With Similar Sized Companies. … has a market capitalization of US$153m, and pays its CEO total annual compensation worth US$1.7m.

Simply Wall St -

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) A Financially Sound Company?

(NASDAQ:SNDX), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Does SNDX's growth rate justify its decision for financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

What Kind Of Shareholders Own Syndax Pharmaceuticals Inc (NASDAQ:SNDX)?

Every investor in Syndax Pharmaceuticals Inc (NASDAQ:SNDX) should be aware of the most powerful shareholder groups. … Generally speaking, as a company grows, institutions will increase their ownership. … With a market capitalization of US$159m, Syndax Pharmaceuticals is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

How Should You Think About Syndax Pharmaceuticals Inc's (NASDAQ:SNDX) Risks?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

When Will Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Turn A Profit?

Syndax Pharmaceuticals Inc's (NASDAQ:SNDX):. … Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. … With the latest financial year loss of -US$60.80m and a trailing-twelve month of -US$67.23m, the US$212.47m market-cap amplifies its loss by moving further away from its breakeven target.

Simply Wall St -

Company Info

Description

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company’s lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; with Tecentriq (atezolizumab) in a Phase Ib/II clinical trials to treat patients with triple-negative breast cancer, and HR+ and HER2- metastatic breast cancer; and with Bavencio (avelumab) in a Phase Ib/II clinical trials for the treatment of ovarian cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I dose escalation trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is in Phase I/Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; Merck KGaA and Pfizer; and AstraZeneca plc. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.

Details
Name: Syndax Pharmaceuticals, Inc.
SNDX
Exchange: NasdaqGS
Founded: 2005
$243,320,095
27,095,779
Website: http://www.syndax.com
Address: Syndax Pharmaceuticals, Inc.
35 Gatehouse Drive,
Building D,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS SNDX Common Stock Nasdaq Global Select US USD 03. Mar 2016
DB 1T3 Common Stock Deutsche Boerse AG DE EUR 03. Mar 2016
Number of employees
Current staff
Staff numbers
38
Syndax Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/16 00:40
End of day share price update: 2019/07/15 00:00
Last estimates confirmation: 2019/07/11
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.